Lilly Tries To Boost Evista Profile Via Comparative Trial With Fosamax
Executive Summary
Lilly will compare the osteoporosis agent Evista (raloxifene) to Merck's Fosamax (alendronate) in a head-to-head trial designed to better position the selective estrogen receptor modulator against its most successful bisphosphonate competitor.